N Hayashi1, H Kinoshita, E Yukawa, S Higuchi. 1. Clinical Pharmacology Section, Clinical Research & Development Division, Chugai Pharmaceutical Co., Ltd., Tokyo, Japan.
Abstract
AIMS: Erythropoietin, a glycoprotein hormone is produced by the kidney and targeted to erythrocyte precursors. Recombinant human erythropoietin (Epoetin beta) has been utilized for therapeutic purposes in renal anaemia or anaemia occurring after auto blood donation or chemotherapy. The administration routes for erythropoietin are normally subcutaneous or intravenous. No population pharmacokinetic analysis, however, has been performed following subcutaneous administration with consideration given for endogenous production. METHODS: In the present study, we have attempted to analyze the pharmacokinetics of erythropoietin after subcutaneous administration in healthy adult male volunteers by using the Nonlinear Mixed Effect Model program (NONMEM) with a model including endogenous erythropoietin production. RESULTS: It has been established that the final estimation of the population mean values of the absorption rate constant (ka), the elimination rate constant (ke), the distribution volume (V) and the endogenous production are 0.0430 h(-1), 0.206 h(-1), 3.141 and 15.7IU h(-1), respectively. For the circadian rhythm of endogenous production, the amplitude was calculated as 9.86% and the peak appeared around 24.00 h. CONCLUSIONS: The values for ke and V are very similar to those previously reported for intravenous administration. The circadian rhythm of endogenous production are also able to be substantiated. The factors influencing ke were found to be serum creatinine and age.
RCT Entities:
AIMS: Erythropoietin, a glycoprotein hormone is produced by the kidney and targeted to erythrocyte precursors. Recombinant humanerythropoietin (Epoetin beta) has been utilized for therapeutic purposes in renal anaemia or anaemia occurring after auto blood donation or chemotherapy. The administration routes for erythropoietin are normally subcutaneous or intravenous. No population pharmacokinetic analysis, however, has been performed following subcutaneous administration with consideration given for endogenous production. METHODS: In the present study, we have attempted to analyze the pharmacokinetics of erythropoietin after subcutaneous administration in healthy adult male volunteers by using the Nonlinear Mixed Effect Model program (NONMEM) with a model including endogenous erythropoietin production. RESULTS: It has been established that the final estimation of the population mean values of the absorption rate constant (ka), the elimination rate constant (ke), the distribution volume (V) and the endogenous production are 0.0430 h(-1), 0.206 h(-1), 3.141 and 15.7IU h(-1), respectively. For the circadian rhythm of endogenous production, the amplitude was calculated as 9.86% and the peak appeared around 24.00 h. CONCLUSIONS: The values for ke and V are very similar to those previously reported for intravenous administration. The circadian rhythm of endogenous production are also able to be substantiated. The factors influencing ke were found to be serum creatinine and age.
Authors: Roman Huber; Jürgen Eisenbraun; Barbara Miletzki; Michael Adler; Rainer Scheer; Reinhild Klein; Christoph H Gleiter Journal: Eur J Clin Pharmacol Date: 2010-05-14 Impact factor: 2.953
Authors: Dale L Phelps; Robert M Ward; Rick L Williams; Kristi L Watterberg; Abbot R Laptook; Lisa A Wrage; Tracy L Nolen; Timothy R Fennell; Richard A Ehrenkranz; Brenda B Poindexter; C Michael Cotten; Mikko K Hallman; Ivan D Frantz; Roger G Faix; Kristin M Zaterka-Baxter; Abhik Das; M Bethany Ball; T Michael O'Shea; Conra Backstrom Lacy; Michele C Walsh; Seetha Shankaran; Pablo J Sánchez; Edward F Bell; Rosemary D Higgins Journal: Pediatr Res Date: 2013-09-04 Impact factor: 3.756